Category : C-Diff

Clostridium difficile infection (CDI) represents a major healthcare concern that causes diarrhea and usually affects people who have recently been treated with antibiotics or have had an extended stay in a healthcare setting. It can also spread easily to others. Although previous experimental research has shown that a fiber-deprived diet leads to a disturbed host colonic epithelium and has an…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

Clostridium difficile infection (CDI) represents a major healthcare concern that causes diarrhea and usually affects people who have recently been treated with antibiotics or have had an extended stay in a healthcare setting. It can also spread easily to others. Although previous experimental research has shown that a fiber-deprived diet leads to a disturbed host colonic epithelium and has an…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

Many questions arise when it comes to probiotics and gut microbiota. By what mechanisms of action can probiotics affect host health? What is the role of probiotics in preventing healthcare-associated infections? Do probiotics affect the intestinal barrier? The Gut Microbiota for Health publishing team has asked a selection of world-leading experts to weigh in on the answers, and we're pleased…

GMFH Editing Team
GMFH Editing Team

Many questions arise when it comes to probiotics and gut microbiota. By what mechanisms of action can probiotics affect host health? What is the role of probiotics in preventing healthcare-associated infections? Do probiotics affect the intestinal barrier? The Gut Microbiota for Health publishing team has asked a selection of world-leading experts to weigh in on the answers, and we're pleased…

GMFH Editing Team
GMFH Editing Team

In the new Gut Microbiota for Health “Clinical Minute” series, we get a scientific expert’s take on gut-microbiota-related questions of interest to healthcare professionals. TOPIC: Should probiotics be used for prevention of Clostridium difficile infection? Dr. Nicole T. Shen is a first year gastroenterology and hepatology fellow in the Division of Gastroenterology and Hepatology at Weill Department of Medicine, Weill…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

In the new Gut Microbiota for Health “Clinical Minute” series, we get a scientific expert’s take on gut-microbiota-related questions of interest to healthcare professionals. TOPIC: Should probiotics be used for prevention of Clostridium difficile infection? Dr. Nicole T. Shen is a first year gastroenterology and hepatology fellow in the Division of Gastroenterology and Hepatology at Weill Department of Medicine, Weill…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Recently, there has been a huge change in the perception of microbial diseases and a shift in the understanding of how to treat them. It is now recognized that there are few disorders that can be attributed to the presence or absence of a single organism. Rather, the structure of the entire community of microbes constituting the human microbiota often…

Melissa Agnello
Melissa Agnello is a postdoctoral scholar at the University of California, Los Angeles. Her research focuses on the bacteria and other resident microbes that live in the mouth, how they cause diseases such as caries, and how manipulating them can lead to new treatments and/or preventions.

Recently, there has been a huge change in the perception of microbial diseases and a shift in the understanding of how to treat them. It is now recognized that there are few disorders that can be attributed to the presence or absence of a single organism. Rather, the structure of the entire community of microbes constituting the human microbiota often…

Melissa Agnello
Melissa Agnello is a postdoctoral scholar at the University of California, Los Angeles. Her research focuses on the bacteria and other resident microbes that live in the mouth, how they cause diseases such as caries, and how manipulating them can lead to new treatments and/or preventions.

Clostridium difficile infection (CDI) is a common infection in which alterations in gut microbiota play an important role in increased susceptibility. Although current research is assessing several clinical features that may predict CDI treatment response, there is a need for consistent predictors of response and recurrence in patients with a first occurrence of CDI. A recent study, led by Dr.…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

Clostridium difficile infection (CDI) is a common infection in which alterations in gut microbiota play an important role in increased susceptibility. Although current research is assessing several clinical features that may predict CDI treatment response, there is a need for consistent predictors of response and recurrence in patients with a first occurrence of CDI. A recent study, led by Dr.…

Andreu Prados
Andreu Prados holds a Bachelor of Science Degree in Pharmacy & Human Nutrition and Dietetics. Science writer specialised in gut microbiota and probiotics, working also as lecturer and consultant in nutrition and healthcare. Follow Andreu on Twitter @andreuprados

In a recent issue of Annals of Internal Medicine, Cammarota et al. showed that the implementation of a fecal microbiota transplantation (FMT) program, available from June 2013 in the A. Gemelli University Hospital, an Italian academic tertiary care centre, led to fewer surgical procedures for severe C. difficile infection (CDI). Between January 2010 and April 2015, 901 patients with CDI…

GMFH Editing Team
GMFH Editing Team

In a recent issue of Annals of Internal Medicine, Cammarota et al. showed that the implementation of a fecal microbiota transplantation (FMT) program, available from June 2013 in the A. Gemelli University Hospital, an Italian academic tertiary care centre, led to fewer surgical procedures for severe C. difficile infection (CDI). Between January 2010 and April 2015, 901 patients with CDI…

GMFH Editing Team
GMFH Editing Team

Fecal microbiota transplantation (FMT), which is up to 90% effective in treating recurrent Clostridium difficile (C. difficile) infection, may or may not be an effective treatment for other conditions. Researchers around the world are investigating its use for ulcerative colitis, Crohn’s disease, and more. Regulatory bodies have not approved its use for conditions other than C. difficile, but that doesn’t stop thousands…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Fecal microbiota transplantation (FMT), which is up to 90% effective in treating recurrent Clostridium difficile (C. difficile) infection, may or may not be an effective treatment for other conditions. Researchers around the world are investigating its use for ulcerative colitis, Crohn’s disease, and more. Regulatory bodies have not approved its use for conditions other than C. difficile, but that doesn’t stop thousands…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Dr. Mark Smith is a postdoctoral associate at Massachusetts Institute of Technology and co-founder of OpenBiome, a nonprofit organization focused on expanding safe access to fecal microbiota transplantation (FMT). Smith attended the Fourth Gut Summit in Barcelona on March 14th and 15th, 2015. (See replays of the event here.) After the summit, he answered some questions for GMFH editors about a…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Dr. Mark Smith is a postdoctoral associate at Massachusetts Institute of Technology and co-founder of OpenBiome, a nonprofit organization focused on expanding safe access to fecal microbiota transplantation (FMT). Smith attended the Fourth Gut Summit in Barcelona on March 14th and 15th, 2015. (See replays of the event here.) After the summit, he answered some questions for GMFH editors about a…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Neha Alang and Colleen R. Kelly recently reported that a patient who had received fecal microbiota transplantation (FMT) developed obesity (1). Although it is impossible to be sure about the role of FMT in this very case, it seems wise to exclude obese donors from FMT. This 32-year-old patient required FMT for recurrent Clostridium difficile infection (CDI). Before FMT she…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.

Neha Alang and Colleen R. Kelly recently reported that a patient who had received fecal microbiota transplantation (FMT) developed obesity (1). Although it is impossible to be sure about the role of FMT in this very case, it seems wise to exclude obese donors from FMT. This 32-year-old patient required FMT for recurrent Clostridium difficile infection (CDI). Before FMT she…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.